References
- Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children—southern California, March–April 2009. MMWR Morb Mortal Wkly Rep 2009;58:400–2.
- World Health Organization. Pandemic (H1N1) 2009—update 79. Geneva: WHO; 2009.
- World Health Organization. DG Statement following the meeting of the Emergency Committee. Geneva: WHO; 2009.
- Na S, Kim MN, Kim WY, Kim W, Hong SB, Lim CM, . Prevalence and clinical features of pneumonia in patients with laboratory-confirmed pandemic influenza A H1N1 2009 infection in South Korea. Scand J Infect Dis 2011;43: 19–26.
- Belgian Working Group on Influenza A(H1N1)v. Influenza A(H1N1)v virus infections in Belgium, May–June 2009. Euro Surveill 2009;14:19270.
- Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, . Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009;361:2507–17.
- Crum-Cianflone NF, Blair PJ, Faix D, Arnold J, Echols S, Sherman SS, . Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis 2009;49:1801–10.
- World Health Organization. WHO Guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. Geneva: WHO; 2009.
- Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845–50.
- Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:1016–24.
- Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009;339: b5106.
- Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2006;3:CD001265.
- Falagas ME, Koletsi PK, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Rello J. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010;65:1330–46.
- Centers for Disease Control and Prevention (CDC). Patients hospitalized with 2009 pandemic influenza A (H1N1)—New York City, May 2009. MMWR Morb Mortal Wkly Rep 2010;58:1436–40.
- Rungrotmongkol T, Intharathep P, Malaisree M, Nunthaboot N, Kaiyawet N, Sompornpisut P, . Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem Biophys Res Commun 2009;385:390–4.
- Burrel S, Roncin L, Lafon ME, Fleury H. Oseltamivir susceptibility in south-western France during the 2007–8 and 2008–9 influenza epidemics and the ongoing influenza pandemic 2009. Euro Surveill 2009;14:19334.
- Chen H, Cheung CL, Tai H, Zhao P, Chan JF, Cheng VC, . Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 2009;15:1970–2.
- Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009;361:2296–7.
- Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Wkly Epidemiol Rec 2009;84:453–9.
- Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667–72.